Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.60 |
| ▸ | HRH2 known ✓ | P25021 | 2/20 | 0.58 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.58 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.58 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.58 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.58 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.58 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.58 |
| ▸ | HTR7 known ✓ | P34969 | 4/20 | 0.50 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.44 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.44 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.44 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.44 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.44 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.44 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.44 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5686168 | 1.00 | HRH1 (0.60) | HRH1HRH2HTR2ADRD3HTR2B | |
| SCHEMBL219876 | 0.99 | HRH1 (0.59) | HRH1HRH2HTR2ADRD3HTR2B | |
| Hydrochloric Acid SCHEMBL10930701 | 0.98 | HRH1 (0.58) | HRH1HRH2HTR2ADRD3HTR2B | |
| SCHEMBL2058761 | 0.97 | HRH1 (0.57) | HRH1HRH2HTR2ADRD3HTR2B | |
| SCHEMBL1569359 | 0.89 | HTR7 (0.50) | HRH1HRH2HTR2ADRD3HTR2B | |
| Hydrochloric Acid SCHEMBL10930120 | 0.88 | HTR7 (0.47) | HRH1HRH2HTR2ADRD3HTR2B | |
| Hydrochloric Acid SCHEMBL7588549 | 0.88 | HRH1 (0.56) | HRH1HRH2HTR2ADRD3HTR2B | |
| Potassium Ion SCHEMBL2058535 | 0.88 | HTR7 (0.49) | HRH1HRH2HTR2ADRD3HTR2B | |
| SCHEMBL2058741 | 0.88 | HRH3 (0.49) | HRH1HRH2HTR2ADRD3HTR2B | |
| Hydrochloric Acid SCHEMBL5624913 | 0.88 | HTR7 (0.51) | HRH1HRH2HTR2ADRD3HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1734918-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING HAIR LOSS AND BENIGN PROSTATIC HYPERPLASIA | LEE EUN-JOO (KR) | 2012-08-01 | — | — | EP | claimed |
| US-20080287459-A1 | Pharmaceutical Composition for Treating Hair Loss and Benign Prostatic Hyperplasia | LEE EUN-JOO | 2008-11-20 | — | — | US | claimed |
| US-20040132743-A1 | Amorphous form of (-)-[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride (levocetirizine dihydrochloride) | DR. REDDY'S LABORATORIES LIMITED DR. REDDY'S LABORATORIES, INC. | 2004-07-08 | — | — | US | claimed |
| WO-2004000823-A1 | AMORPHOUS FORM OF(-)-}2-}4-}(4-CHLOROPHENYL)-PHENYL METHYL}-1-PIPERAZINYL] ETHOXY] ACETIC ACID DIHYDROCHLORIDE (LEVOCETRIRIZINE DIHYDROCHLORIDE) | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-12-31 | — | — | WO | claimed |
| WO-2003104212-A1 | A NOVEL AMORPHOUS FORM OF [2-[4-[(4-CHLOROPHENYL)-PHENYL METHYL]-1- PIPERAZINYL] ETHOXY] ACETIC ACID DIHYDROCHLORIDE (CETIRIZINE DIHYDROCHLORIDE) | DR.REDDY'S LABORATORIES LTD. (IN) | 2003-12-18 | — | — | WO | claimed |
| WO-2020232353-A1 | SENSORS AND METHODS USING ELECTROCHEMILUMINESCENCE OF METAL NANOCLUSTERS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| EP-2297122-B1 | NEW PROCESS FOR THE PREPARATION OF LEVOCETIRIZINE AND INTERMEDIATES THEREOF | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2014-05-21 | — | — | EP | disclosed |
| EP-2167479-B1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LTD (IN) | 2013-09-11 | — | — | EP | disclosed |
| EP-1734918-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING HAIR LOSS AND BENIGN PROSTATIC HYPERPLASIA | LEE EUN-JOO (KR) | 2012-08-01 | — | — | EP | disclosed |
| US-8088775-B2 | Pharmaceutical composition for treating hair loss | KIM, SOLOMON L. | 2012-01-03 | — | — | US | disclosed |
| US-8084606-B2 | Process for preparation of substantially optically pure levorotatory and dextrorotatory enantiomers of cetirizine using novel intermediates | SYMED LABS LIMITED (IN) | 2011-12-27 | — | — | US | disclosed |
| US-20110172425-A1 | NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES | CALYX CHEMICALS AND PHARMACEUTICALS PVT. LTD. (IN) | 2011-07-14 | — | — | US | disclosed |
| US-6255487-B1 | PREPARING 2-(2-(4-((4-CHLOROPHENYL)PHENYLMETHYL)-1-PIPER-AZINYL)ETHOXY)ACETIC ACID VIA REACTING SUBSTITUTED (2-((1-PIPERAZINYL)ETHOXY)METHYL COMPOUND WITH A DIPHENYLMETHYL HALIDE, THEN HYDROLYZING IN ALCOHOLIC MEDIUM WITH ACID/BASE | UCB, S.A. (BE) | 2001-07-03 | — | — | US | disclosed |
| WO-2001032641-A1 | PROCESS FOR PREPARING PIPERAZINE-SUBSTITUTED ALIPHATIC CARBOXYLATES | SALSBURY CHEMICALS, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-1071461-A1 | METHODS AND COMPOSITIONS USING CETIRIZINE IN COMBINATION WITH LEUKOTRIENE INHIBITORS FOR TREATING CONDITIONS RESPONSIVE TO LEUKOTRIENE INHIBITION | SEPRACOR, INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| US-6140501-A | CHEMICAL INTERMEDIATES | UCB, S.A. (BE) | 2000-10-31 | — | — | US | disclosed |
| WO-2000052000-A1 | A PROCESS FOR THE PREPARATION OF 2-{2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY}ACETIC ACID COMPOUNDS OR SALTS THEREOF | A/S GEA FARMACEUTISK FABRIK (DK) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999052553-A1 | METHODS AND COMPOSITIONS USING CETIRIZINE IN COMBINATION WITH LEUKOTRIENE INHIBITORS FOR TREATING CONDITIONS RESPONSIVE TO LEUKOTRIENE INHIBITION | SEPRACOR INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| US-5478941-A | Useful in treatment of asthma, allergies, inflammation and anxiety; antihistaminic activity | U C B, S.A. (BE) | 1995-12-26 | — | — | US | disclosed |
| US-4525358-A | ANTIHISTAMINES, ANTIALLERGENS, ANTISPASMODICS, BRONCHODILATORS | UCB PHARMACEUTICALS, INC. (US) | 1985-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132743-A1 | Amorphous form of (-)-[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride (levocetirizine dihydrochloride) | HRH4, HRH1, HRH2 | HRH1 2/4885HRH2 3/4885HTR2A 121/4885 |
| US-20080287459-A1 | Pharmaceutical Composition for Treating Hair Loss and Benign Prostatic Hyperplasia | SHBG, CYP17A1, NR5A1 | HRH1 3049/4885HRH2 3256/4885HTR2A 1417/4885 |
| US-20110172425-A1 | NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES | ALK, WIZ, HACL2 | HRH1 1046/4885HRH2 205/4885HTR2A 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.